Epstein Secrets

apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where

g end and weakness in US equities is unusual of late and t=lls us there is implications for risk parity portfolios. =/p> We expect a 165k change in Non-Farm Pay=olls on Friday but a strong number sets up for some left hand tail risk in US Fixed Income. Risk parity portfolios own more bonds t=an equities (du

l to drive shareholder return. N=xt catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm :=17;s US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval=of AGN generics deal. We continue to like TEVA's positioning in generic=pharma where

d long end and weakness in US equities is unusual of late and tel=s us there is implications for risk parity portfolios. We expect a 165k change in Non-Farm Pay=olls on Friday but a strong number sets up for some left hand tail risk in=US Fixed Income. Risk parity portfolios own more bonds t=an equities (du

apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where

g end and weakness in US equities is unusual of late and t=lls us there is implications for risk parity portfolios. =/p> We expect a 165k change in Non-Farm Pay=olls on Friday but a strong number sets up for some left hand tail risk in US Fixed Income. Risk parity portfolios own more bonds t=an equities (du

apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where

g end and weakness in US equities is unusual of late and t=lls us there is implications for risk parity portfolios. =/p> We expect a 165k change in Non-Farm Pay=olls on Friday but a strong number sets up for some left hand tail risk in US Fixed Income. Risk parity portfolios own more bonds t=an equities (du